Bicara Therapeutics Inc.(BCAX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Bicara Therapeutics Inc. (BCAX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BCAX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Bicara Therapeutics Inc. reports net income of $-55.4M, free cash flow of $-44.3M. Top institutional holders of BCAX by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Siren, L.L.C., based on the most recent SEC filings. BCAX trades on the Nasdaq exchange and files with the SEC under CIK 2023658. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bicara Therapeutics Inc. directly from SEC EDGAR.